Immatics (IMTX) Equity Income (2021 - 2025)
Immatics (IMTX) posted Equity Income of $79.6 million for Q2 2025, up 310.99% sequentially from $19.4 million in Q2 2024, and up 310.99% YoY from $19.4 million in Q2 2024.
Immatics (IMTX) Equity Income (2021 - 2025) Analysis & Trends
Immatics has reported Equity Income for 5 years, with the latest figure at $79.6 million in Q2 2025.
- Quarterly Equity Income rose 310.99% year-over-year to $79.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $44.6 million (up 638.66% YoY) and the FY2025 annual result came in at -$221.9 million, down 1447.51% from the prior year.
- Equity Income advanced to $79.6 million in Q2 2025 per IMTX's latest filing, from $19.4 million in the prior quarter.
- Over five years, Equity Income peaked at $96.1 million in Q1 2022 and troughed at -$28.8 million in Q3 2023.
- A 5-year average of $9.6 million and a median of -$2.1 million in 2021 frame the typical range for Equity Income.
- The widest YoY moves for Equity Income: up 449.38% in 2022, down 165.8% in 2022.
- Over 5 years, Equity Income stood at -$19.2 million in 2021, then retreated by 22.42% to -$23.5 million in 2022, then decreased by 8.94% to -$25.6 million in 2023, then soared by 175.65% to $19.4 million in 2024, then soared by 310.99% to $79.6 million in 2025.
- According to Business Quant data, Equity Income over the past three periods registered $79.6 million, $19.4 million, and -$25.6 million for Q2 2025, Q2 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 79.63 Mn |
| Jun 30, 2024 | 19.38 Mn |
| Dec 31, 2023 | -25.61 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | -23.51 Mn |
| Sep 30, 2022 | -21.11 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |